Showing 151–175 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Yong Soo Kwon
…nt adverse drug reactions associated with complex treatment regimens involving multiple drugs administered over prolonged periods. However, recent clinical trials, such as Nix-TB, ZeNix, NExT, MDR-END, TB-PRACTECAL, and BEAT-India, have demonstrated that shorter oral regimens yie…
О. М. Raznatovska, S. I. Tertishniy, V.G. Syusyuka, A.V. Fedorec, Т. К. Sahaidak, et al.
Background. According to World Health Organization (WHO), experimental studies performed in rats and rabbits have revealed no evidence of harmful side effects of bedaquiline to the fetus. WHO points out that, given the lack of adequate and controlled studies on the effects of bed…
Soedarsono Soedarsono, Vicky Reinold Christofel Rampengan, Catur Agustiyanto, Yong‐Soon Cho
Introduction: The World Health Organization (WHO) has recommended the 9-month all-oral regimen for multidrug-resistant tuberculosis (MDR-TB) treatment. This regimen is expected to increase the treatment success rate. Bedaquiline, levofloxacin, and clofazimine are QT-prolonging dr…
Alena Skrahina, Natalia Yatskevich, Henadz Hurevich, Viatcheslav Grankov, Dmitry Klimuk, et al.
<b>Background:</b> New and repurposed TB drugs and shorter regimens can radically change the landscape for treating MDR-TB. In December 2019, the WHO issued “Rapid Communication” related to MDR-TB management; WHO reiterated their earlier recommendation that a majority of MDR-TB p…
Wenhong Zhang, PhD.
…ontrol is poor adherence to long-term and complex treatment regimens. This is a multicenter prospective, non-inferiority randomized controlled study. The purpose of our study is a) to evaluate the tolerability, efficacy and pharmacokinetics/pharmacodynamics (PK/PD) of the high-d…
Günther G, Guglielmetti L, Kherabi Y, Duarte R, Lange C
…ow accessibility of DST for pretomanid. Equal access to new regimens is urgently needed in Europe and a rapid scale up of DST, especially for pretomanid, is important to prevent unnoticed spread of drug resistance.
Jouego CG, Gils T, Piubello A, Mbassa V, Kuate A, et al.
…of patients treated with STR, FQr-mTR and SLIr-mTR as final regimens, respectively. Three (0.6%) patients acquired FQr during treatment. Early mortality occurred in 4.1% (29/709) and was associated with being HIV positive, male sex and being underweight. Overall mortality was ass…
Putra ON, Yulistiani Y, Soedarsono S
Background A regimen containing bedaquiline-delamanid is recommended in management of drug-resistant tuberculosis (DR TB) to increase a success rate. However, this regimen was rare in a clinical setting due to a potential risk of QT prolongation. Several studies have reported the…
Tucker EW, Dooley KE
Tuberculosis (TB) treatment regimens have been extrapolated from adults to children. However, pediatric disease merits different treatment strategies to avoid under- or over-treatment. While animal models have been pivotal in identifying effective regimens for adult disease, pedi…
Sarmat Z. Suleimanov, М. В. Синицын
… the inclusion of linezolid and bedaquiline in chemotherapy regimens. Material and methods. A non-randomized, continuous, single-center retrospective study was conducted involving 114 patients who underwent surgery at the National Medical Research Center for Phthisiopulmonology a…
Ngoc NB, Vu Dinh H, Thuy NT, Quang DV, Huyen CTT, et al.
…ety of patients on longer injectable-based MDR-TB treatment regimens using active pharmacovigilance data. Method We conducted an observational, prospective study based on active pharmacovigilance within the national TB program. A total of 659 MDR-TB patients were enrolled and fol…
Kalolo A, Lalashowi J, Pamba D, Shayo PJ, Gitige C, et al.
Introduction Tanzania is adapting a shortened injectable-free multidrug resistant tuberculosis (MDR-TB) regimen, comprising new drugs such as bedaquiline and delamanid and repurposed drugs such as clofazimine and linezolid. The regimen is implemented using a pragmatic prospective…
du Cros P, Khamraev A, Tigay Z, Abdrasuliev T, Greig J, et al.
…s conditionally recommended standardised shorter 9-12-month regimens for multidrug-resistant (MDR) tuberculosis (TB) treatment. We conducted a prospective study of a shorter standardised MDR-TB regimen in Karakalpakstan, Uzbekistan. Methods Consecutive adults and children with co…
B K, Singla R, Singla N, V V, Singh K, et al.
…rugs. Under certain conditions, the WHO recommends standard regimens lasting 9 to 11 months rather than individual regimens lasting at least 18-20 months. The current study sought to identify factors associated with treatment outcomes in RR/MDR-TB patients receiving an injection-…
Gaki Nima, Thinley Dorji, Chencho Dorji, Tandin Zangpo
**BACKGROUND AND AIMS:** Bhutan first introduced the Shorter Regimen, consisting of a combination of Amikacin, Clofazamine, Ethionamide, Ethambutol, high dose Isoniazid, Moxifloxacin and Pyrazinamide, for the treatment of rifampicin or multidrug resistant tuberculosis (RR/MDR-TB)…
Sayed Idrees Shah, Abdul Ghafoor, Shafiq Ur Rahman, Abidullah, Nafees Ahmad, et al.
…outcomes in MDR/RR-TB patients receiving all oral treatment regimens. **STUDY DESIGN:** A total of 242 eligible MDR/RR-TB patients treated at two different study sites from June 2019 to December 2021 were included in this study. **MEASURES AND OUTCOMES:** Patients' sociodemogra…
Cohen DB, Meghji J, Squire SB
Objective To assess the clinical outcomes of patients prescribed the World Health Organization (WHO) Category II retreatment regimen for tuberculosis (TB). Design A systematic review of the literature was performed by searching Medscape, Embase and Scopus databases for cohort stu…
Jackson Dumo Lodiong L, Izudi J, Amanee Elias Lumori B
…nt success among people with MDR/RR-TB on bedaquiline-based regimens in the country. The weaknesses are the smaller sample size, we analyzed data spanning a relatively shorter period, and alcohol use was measured by self-reporting, this might have underestimated its association w…
Walsh KF, Souroutzidis A, Vilbrun SC, Peeples M, Joissaint G, et al.
Multidrug-resistant tuberculosis (MDR-TB) outcomes are poor partly because of the long treatment duration; the World Health Organization conditionally recommends a shorter course regimen to potentially improve treatment outcomes. Here, we describe the drug susceptibility patterns…
Rina Liang, James C M Brust, Caitlin Reed, Vincent Escuyer, Derek T Armstrong, et al.
…oxifloxacin (BPaL/M) are recommended oral 6-month treatment regimens for multidrug- or rifampin-resistant (MDR/RR) tuberculosis (TB). Since the US rollout of these regimens in 2019, the US Centers for Disease Control and Prevention (CDC) and partners have identified patients who …
Xiaomeng Hu, Changhao Cheng, Qian Jin, Wu Jin, Qiaoyan Dong, et al.
…ystem, breast, lymph node) received individualized all-oral regimens. Regimens combined DLM with bedaquiline (BDQ), linezolid (LZD), fluoroquinolones, and companion drugs for ≥ 15 months. Follow-up imaging demonstrated significant lesion resolution in all ca…
Garcia-Prats AJ, Starke JR, Waning B, Kaiser B, Seddon JA
…h the previous standard therapy of at least 6 months, 2 new regimens lasting for only 4 months for the treatment of DS-TB have been studied and are recommended by the World Health Organization (WHO), along with a shortened 6-month regimen for treatment of DS-TB meningitis. In add…
Strydom N, Gupta SV, Fox WS, Via LE, Bang H, et al.
…ics (PKs) in TB patients is necessary to optimize treatment regimens at all infection sites, to identify patients at risk, to improve existing regimens, and to advance development of novel regimens. Using drug-level data in plasma and from 9 distinct pulmonary lesion types (vascu…
Lalashowi J, Mvungi H, Mwaisango Z, Pamba D, Mohamed A, et al.
…within 6 months of Removed Injectable modified Short-course regimens for EXpert MDR-TB (RISE) study implementation and the second phase within 15 months of implementation using the same reference populations. Settings 18 health facilities across eight regions of Tanzania. Partici…
Abraham Y, Assefa DG, Hailemariam T, Gebrie D, Debela DT, et al.
…rculosis (DR-TB) remains a threat to public health. Shorter regimens have been proposed as potentially valuable treatments for multidrug or rifampicin resistant tuberculosis (MDR/RR-TB). We undertook a systematic review and network meta-analysis to evaluate the efficacy and safet…